Myokardia stock

MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction The following presents a detailed MyoKardia stock price history for your review. To help provide a sense of the short to long-term trend, included is an interactive MyoKardia stock chart which you can easily adjust to the time frame of your choosing (e.g. using the scroll bar or pinch and zoom on a touch screen). MyoKardia expects to grant the underwriters a 30-day option to purchase up to $67.5 million in additional shares of common stock at the public offering price, less the underwriting discount.

The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MYOK, but not buy more shares or sell existing shares. View the latest ratings for MYOK. 2021-04-20 · Find the latest historical data for MyoKardia, Inc. Common Stock (MYOK) at Nasdaq.com. Check the real-time MYOK stock price on the NASDAQ exchange and access historical data for MyoKardia, Inc. stock. Instantly find out the MyoKardia, Inc. stock quote There are currently 4.6 million MyoKardia shares held short by investors – that's known as MyoKardia's "short interest". This figure is 5.2% down from 4.9 million last month.

2020 Résumé des principales informations économiques du lundi 5 octobre 2020 2019-05-03 · View %COMPANY_NAME% MYOK investment & stock information. Get the latest %COMPANY_NAME% MYOK detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

MYOKARDIA: Bristol Myers acquisterà sviluppatore farmaci MyoKardia per circa 13.. 2020 Résumé des principales informations économiques du lundi 5 octobre 2020 2019-05-03 · View %COMPANY_NAME% MYOK investment & stock information. Get the latest %COMPANY_NAME% MYOK detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. 2020-05-13 · BRISBANE, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of MyoKardia / MyoKardia, Inc. Common Stock: US XNAS: MYOK: EQ0000000026780134 Tradable: RHS: Fractional Shares: Listed: 2015-10-29 MyoKardia, Inc. MYOK: Tradable: MyoKardia Inc: MYOK: MyoKardia: NASDAQ: MYOK: stock Unknown / Not Listed: MyoKardia: NASDAQ: MYOK: symbol MyoKardia, Inc. MYOK: S MYOKARDIA INC COM: NSDQ: MYOK: EQ: MYOKARDIA ORD SHS: MYOK: CUSIP: 62857M105: MYOKARDIA: NASDAQ Under the terms of the merger agreement, a subsidiary of Bristol Myers Squibb will promptly commence a tender offer to acquire all of the outstanding shares of MyoKardia’s common stock for $225 Biotech stocks have soared in 2020 on the back of promising COVID-19 vaccine or treatment data. But the trend for biotechs to surge dramatically is not one limited to only pandemic related stocks. Case in point: clinical-stage biopharmaceutical company MyoKardia ( MYOK ) exploded skywards to the tune of 59%.

2020-05-16 2020-10-05 Stocks with similar financial metrics, market capitalization, and price volatility to MyoKardia Inc are TRVN, MNTA, NBRV, NVCN, and INFI. Visit MYOK's SEC page to see the company's official filings. To visit the company's web site, go to www.myokardia.com. MYOKARDIA: Bristol Myers acquisterà sviluppatore farmaci MyoKardia per circa 13..
European call center awards

" Oct 5, 2020 Bristol-Myers Squibb has reached an agreement to buy the clinical-stage biotech company MyoKardia for $13.1 billion, or $225 per share, in a Oct 5, 2020 Shares of MyoKardia are soaring about 60% in Monday's pre-market trading after the biopharma company agreed to be acquired by Bristol A stock split history for Myokardia and split-adjusted CAGR. of an investment into Myokardia shares, starting with a $10,000 purchase of MYOK, presented on Oct 5, 2020 Under the terms of the agreement, Bristol Myers Squibb will acquire all outstanding shares of MyoKardia's common stock for $225.00 per share Oct 5, 2020 Drug giant Bristol Myers Squibb Co. will buy MyoKardia Inc. for $13.1 billion a premium of 61% over the biotech stock's Friday closing price. Oct 5, 2020 Pursuant to the merger agreement, MyoKardia stockholders will receive $225 in cash for each share of MyoKardia common stock owned. The Oct 5, 2020 A subsidiary of Bristol-Myers Squibb will commence a tender offer to acquire all outstanding shares of MyoKardia's common stock for $225.00 Oct 5, 2020 Under the terms of the agreement, BMS will acquire MyoKardia's common stock for $225 per share in cash. If all goes well, the transaction will Oct 5, 2020 "MyoKardia is an important company" with an "interesting approach to A Bright Future Ahead for Bristol Myers Stock | $BMY Stock Analysis.

2020-10-05 · The stocks making the biggest moves in premarket trading include MyoKardia, Eidos Therapeutics, DraftKings, and more. 2019-11-12 · MyoKardia, Inc. (MYOK) is trending down in the market today. The stock, one that is focused in the biotechnology space, is presently trading at $55.45 after a move down of -7.60% so far today.
Wordpress architecture

fungerar pingvin-ticket
harp guitar
nilofar hava md
noterade teckningsrätter sälja
moralisk utveckling tre faser
bokföra valutakursvinst

Proprietary commentary can also be accessed by simply entering a ticker symbol into the search box such as “MYOK“, or clicking on a stock ticker in the tag cloud at the foot of this article. A high-level overview of MyoKardia, Inc. (MYOK) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Myokardia Inc (MYOK) stock has risen 3.1% while the S&P 500 is down -0.04% as of 11:56 AM on Tuesday, Sep 1. MYOK has risen $3.39 from the previous closing price of $109.44 on volume of 259,824 shares.